Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 8/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174248 | 0.84 | VDR (0.48) | MAPTVDRNPC1 | |
| SCHEMBL31174250 | 0.84 | VDR (0.48) | MAPTVDRNPC1 | |
| SCHEMBL900164 | 0.84 | VDR (0.48) | MAPTVDRNPC1 | |
| SCHEMBL1701321 | 0.81 | MAPT (0.41) | MAPTRPS6KA5DYRK1ARPS6KB1CDK2 | |
| SCHEMBL19857776 | 0.81 | NPC1 (0.38) | MAPTVDRNPC1 | |
| SCHEMBL4073539 | 0.80 | VDR (0.45) | MAPTVDRNPC1 | |
| SCHEMBL6943964 | 0.78 | CYP1A2 (0.42) | MAPT | |
| SCHEMBL4071076 | 0.77 | NPC1 (0.39) | MAPTBRD4VDRNPC1 | |
| SCHEMBL6947490 | 0.76 | BRD4 (0.36) | MAPTBRD4NPC1 | |
| SCHEMBL23932593 | 0.72 | VDR (0.35) | MAPTBRD4VDRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-7629337-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7183273-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2007-02-27 | — | — | US | disclosed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | disclosed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| EP-1244450-A4 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1244450-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6432976-B1 | ANALGESICS; SIDE EFFECT REDUCTION | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001032179-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | MAPT 4837/4885RPS6KA5 3206/4885DYRK1A 3944/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | MAPT 4468/4885RPS6KA5 2907/4885DYRK1A 4586/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | MAPT 4713/4885RPS6KA5 3335/4885DYRK1A 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.